menu

Medical Program: Update on Remdesivir, Investigational Antiviral for COVID-19

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Update on Remdesivir, Investigational Antiviral for COVID-19

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    This special episode of The Drug Report provides an update regarding the antiviral Remdesivir, which is the first investigational therapeutic to be studied under an FDA-approved NIH adaptive randomized controlled clinical trial for hospitalized COVID-19 patients. Currently, there are three options through clinical trials for obtaining remdesivir for the treatment of hospitalized patients with COVID-19 and pneumonia in the United States, as pharmacist Dr. Linda Bernstein explains.

    Published April 10, 2020

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    This special episode of The Drug Report provides an update regarding the antiviral Remdesivir, which is the first investigational therapeutic to be studied under an FDA-approved NIH adaptive randomized controlled clinical trial for hospitalized COVID-19 patients. Currently, there are three options through clinical trials for obtaining remdesivir for the treatment of hospitalized patients with COVID-19 and pneumonia in the United States, as pharmacist Dr. Linda Bernstein explains.

    Published April 10, 2020

Facebook Comments

Schedule16 Oct 2021